Disc Medicine’s Bitopertin Data Revive FDA Hopes as IRON Stock Surges
Disc Medicine’s bitopertin data delivered a 41.4% biomarker reduction and more pain-free hours, reviving debate over IRON’s FDA prospects.
Centrus Energy’s $116 Million Westerman Deal Puts Domestic Centrifuge Capacity in Focus
Centrus Energy’s planned $116 million acquisition of Westerman could deepen its domestic centrifuge manufacturing footprint and reinforce the US nucle…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
TriGemX Bio Plans $600 Million SPAC Merger With TCGX
TriGemX Bio plans to enter public markets through a $600 million merger with TCGX, adding a new biotech name to the US S…
Disc Medicine Stock Jumps 70% After Positive Phase 3 Bitopertin Results
Disc Medicine’s $IRON surged more than 70% after positive Phase 3 data for bitopertin, putting a potential FDA filing in…
CoreWeave Credit Stress Deepens as AI Sell-Off Pushes Volatility Higher
CoreWeave’s rising bond yields and credit-default swaps are flashing caution as AI and chip stocks sell off and the VIX …
Brent Crude Tops $110 as Middle East Supply Risks Put Energy Traders on Alert
Brent crude rises above $110 as tanker incidents and disrupted infrastructure reports lift fuel futures and raise inflat…
Moderna’s Nasdaq-100 Inclusion Tests Investor Confidence in Its Oncology Pivot
Moderna’s Nasdaq-100 inclusion may bring passive-fund demand as Phase 3 melanoma data puts its oncology pivot under clos…
CoreWeave Credit Stress Deepens as AI Sell-Off Pushes VIX Above 22
CoreWeave’s widening credit stress is colliding with a broader AI sell-off, sending the VIX above 22 and spotlighting fi…
Ascendis Pharma Stock Slips Despite Positive European Opinion for Already-Approved YUVIWEL
ASND shares closed down 0.6% after a positive European opinion for YUVIWEL, highlighting how investors distinguish fresh…
Opus Genetics Wins FDA Approval for Presbyopia Treatment: What IRD Investors Should Watch Next
Opus Genetics received FDA approval for Phentolamine Ophthalmic Solution, creating a potential catalyst as investors ass…
Omeros Stock Breaks Key Support After Second EU Rejection of Narsoplimab
Omeros shares fell below key support after the EMA rejected narsoplimab again, highlighting the split between US approva…